亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

There Is No Difference in Safety and Efficacy Mechanical Thrombectomy alone or Mechanical Thrombectomy with Tirofiban for Patients Undergoing Treatment of Large Vessel Occlusion and Underlying Intracranial Atherosclerosis

替罗非班 医学 溶栓 冲程(发动机) 人口统计学的 外科 内科学 麻醉
作者
Hari Movva,Rani Rabah,Wondwossen G Tekle,Laurie Preston,Hari Kotta,Ameer E Hassan
出处
期刊:Interdisciplinary Neurosurgery [Elsevier]
卷期号:: 101383-101383
标识
DOI:10.1016/j.inat.2021.101383
摘要

Mechanical thrombectomy (MT) is a widely proven method to treat acute ischemic stroke (AIS) during mechanical thrombectomy and acute stenting and angioplasty is a topic discussed till this day regarding safety and efficacy. However, intravenous glycoprotein IIb/IIIa agents such as Tirofiban have become a more common thing. We report the analysis of all AIS patients treated with Tirofiban + MT vs. MT alone. Using a prospectively collected endovascular database at a CSC between 2013 and 2019, workflow, and outcomes were recorded. Patients are given Tirofiban undergoing mechanical thrombectomy and patients undergoing mechanical thrombectomy alone were analyzed to obtain baseline demographics, modified Ranking Scale (mRS) at discharge, and 90 days follow up, pre and post thrombolysis in cerebral infarction (TICI), mortality rate, and hemorrhage rates. There was a total of 169 patients during the study period (average age 68.18 ± 14, 41.42% female). Analysis of 36 patients from the Tirofiban + MT group (average age 69.25 ± 14.18, 27.77% female), and 133 patients from the MT alone was performed (average age 67.89 ± 13.99, 45.11%), see Table 3 for baseline characteristics and outcomes. Four patients (11.11%) in the Tirofiban + MT group had symptomatic hemorrhage versus fourteen patients (10.53%) in the MT alone group (p = .919). There was no significant difference in mortality between the two groups (p = .622). Tirofiban in addition to MT does not increase the risk of symptomatic hemorrhage or mortality. More extensive studies are warranted to prove the safety and efficacy of tirofiban and MT in AIS with tandem lesions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage应助蝈蝈采纳,获得30
3秒前
ooooyasumi完成签到,获得积分10
5秒前
11秒前
19秒前
NexusExplorer应助吵吵robot采纳,获得10
45秒前
50秒前
姚老表完成签到,获得积分10
54秒前
55秒前
LU完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
bkagyin应助KSung采纳,获得10
1分钟前
体贴问丝完成签到 ,获得积分10
1分钟前
2分钟前
KSung发布了新的文献求助10
2分钟前
桃园奈奈露完成签到,获得积分10
2分钟前
深情安青应助科研通管家采纳,获得10
2分钟前
隐形曼青应助科研通管家采纳,获得10
2分钟前
Jasper应助科研通管家采纳,获得10
2分钟前
英勇背包完成签到,获得积分10
2分钟前
无名完成签到,获得积分10
2分钟前
李健应助bosslin采纳,获得10
2分钟前
务实怀柔完成签到 ,获得积分10
2分钟前
3分钟前
hayek完成签到,获得积分10
3分钟前
3分钟前
布通完成签到,获得积分10
4分钟前
LANGYE发布了新的文献求助10
4分钟前
寻道图强应助科研通管家采纳,获得30
4分钟前
寻道图强应助科研通管家采纳,获得30
4分钟前
蝈蝈发布了新的文献求助30
4分钟前
碧蓝香芦完成签到 ,获得积分10
4分钟前
英勇背包发布了新的文献求助10
4分钟前
5分钟前
布通发布了新的文献求助10
5分钟前
zz给zz的求助进行了留言
5分钟前
爱笑的眼睛完成签到,获得积分10
5分钟前
二分三分完成签到,获得积分10
5分钟前
5分钟前
Akim应助LIn采纳,获得10
5分钟前
高分求助中
Sustainability in Tides Chemistry 1500
Handbook of the Mammals of the World – Volume 3: Primates 805
拟南芥模式识别受体参与调控抗病蛋白介导的ETI免疫反应的机制研究 550
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3068019
求助须知:如何正确求助?哪些是违规求助? 2722010
关于积分的说明 7475912
捐赠科研通 2369097
什么是DOI,文献DOI怎么找? 1256116
科研通“疑难数据库(出版商)”最低求助积分说明 609454
版权声明 596795